On this page
Published: January 25, 2024 · Last reviewed: May 1, 2026
Key Takeaways
- Cybersecurity funded before architecture freeze is a design cost. Funded after, it is a redesign cost, and the difference shows up in submission timelines.
- Section 524B turns your filed postmarket vulnerability plan into an enforceable commitment, not a one-time premarket document.
- A missed or unstaffed postmarket program is a common trigger for Warning Letters and recalls, not just a compliance gap.
- The FDA's cybersecurity review is not a separate track from your 510(k) or PMA timeline. Cybersecurity deficiencies delay the entire submission.
- Treating an SBOM as a submission artifact rather than a monitored asset removes your ability to answer "are we affected" when a new CVE lands.
- The business exposure from cybersecurity failure extends past the FDA to hospital procurement reviews and contractual liability with health systems.
Part of our FDA 2026 medical device cybersecurity submission series. For the full overview, start with FDA Cybersecurity Requirements for Medical Devices (2026).
For MedTech executives, medical device cybersecurity is a budget and timeline decision, not a technical afterthought: threat modeling before architecture freeze costs weeks, threat modeling after freeze costs a redesign. Section 524B makes the postmarket vulnerability plan you file a legal commitment the FDA can enforce after clearance. Fund it like a product requirement, on the same timeline as design, and it stops adding review cycles to your submission.
The cost of medical device cybersecurity is not the line item in the engineering budget. It is the review cycle added when a reviewer sends an Additional Information request, the redesign forced when a threat model is bolted on after architecture freeze, and the postmarket obligation that stays enforceable for the life of the device after clearance. Most executives budget for the first cost and get blindsided by the other two. This playbook is written for the decisions that sit above engineering: when to fund cybersecurity, what Section 524B actually exposes the company to, and what it costs the business when a postmarket program exists on paper but not in practice.
Why This Matters
The FDA's premarket cybersecurity expectations were finalized in September 2023, revised in draft form in June 2025, and finalized again as Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions on February 3, 2026. Section 524B of the FD&C Act sits alongside that guidance and applies to any "cyber device," meaning software that connects to the internet with the potential for a cybersecurity vulnerability.
For an executive, the guidance and the statute together mean cybersecurity is no longer a one-time gate before clearance. It is a lifecycle obligation that the company has to staff and fund after the device ships, and the FDA has enforcement tools, including Refuse to Accept determinations and Warning Letters, for companies that treat the filed plan as paperwork rather than an operating program.
When should cybersecurity get funded in the product timeline?
Cybersecurity should be funded before the system architecture is locked, because the cost of adding it afterward is a redesign, not an addition. A threat model built while interfaces are still being decided shapes those decisions. A threat model built after the architecture is frozen has to work around decisions already made, and the mismatches that creates are what reviewers flag.
| When cybersecurity work starts | Typical impact on timeline | Typical impact on submission risk |
|---|---|---|
| Before architecture freeze | Runs in parallel with design, absorbed into the normal schedule | Lower: threat model and architecture describe the same system |
| After architecture freeze, before submission | Requires revisiting design decisions already made | Higher: rework often surfaces new interfaces late |
| At submission, in response to a deficiency | Adds one or more Additional Information review cycles | Highest: risk of Refuse to Accept or repeated deficiency rounds |
Fund threat modeling and security architecture review as a design-phase activity with its own line item, not as a subtask absorbed into general engineering. A program with no dedicated cybersecurity budget line before architecture freeze is the pattern behind almost every late-stage cybersecurity delay we see.
What does Section 524B actually expose the business to?
Section 524B requires cyber device sponsors to submit a postmarket vulnerability monitoring plan, maintain processes to identify and patch vulnerabilities, and provide a software bill of materials, and once filed, that plan is treated as a commitment the company has to operate, not a document it can leave unstaffed. It applies across 510(k), De Novo, PMA, PDP, and HDE submissions, so there is no pathway that avoids it for a connected device.
The exposure does not stop at the FDA. Hospital procurement teams increasingly request the same evidence (MDS2 forms, SBOM, vulnerability response commitments) during purchasing review, so a weak postmarket program can cost sales cycles even for a device that already cleared. A mismatch between the device as marketed and the device as cleared, caused by an unstaffed postmarket plan, is also one of the more direct paths to a Warning Letter.
Making a cybersecurity investment decision for a cyber device?
Blue Goat Cyber is a medical-device-only cybersecurity firm. Our team scopes the threat modeling, testing, and postmarket program budget against your actual submission timeline. Medical device penetration testing
What happens to a submission when cybersecurity is treated as a checkbox?
Treating cybersecurity as a checkbox produces documents that do not agree with each other, and reviewers respond to that with Additional Information requests, which is the direct cause of longer review timelines. A threat model written to satisfy a template, disconnected from the actual architecture, is the most common version of this failure.
The cybersecurity review is not a side track from the rest of your 510(k), De Novo, or PMA review. Cybersecurity deficiencies delay the whole submission, because reviewers will not clear the device while an open question about vulnerability management remains. Budgeting cybersecurity as a genuine workstream, with its own milestones inside the submission timeline, is what keeps it from becoming the reason the whole submission slips.
What does a postmarket cybersecurity failure cost after clearance?
A postmarket cybersecurity failure costs more than the incident response itself, because it also exposes the gap between the plan filed with the FDA and the program actually running. When a widely used software component gets a new CVE and there is no SBOM monitoring to catch it, no triage process to assess patient impact, and no coordinated disclosure workflow to manage the response, the company is improvising in front of a regulator, customers, and potentially the press at the same time.
That improvisation is what turns a routine vulnerability disclosure into a Warning Letter, a field action, or a lost hospital contract. The fix is operational, not technical: assign an owner for vulnerability intake, fund SBOM monitoring as an ongoing service rather than a one-time deliverable, and rehearse the coordinated disclosure process before you need it under pressure.
Why the FDA's Rules Function as Protection, Not Red Tape
See also: CVSS Scoring for Medical Devices: A Complete Walkthrough, Healthcare Cybersecurity Companies: A Buyer's Selection Guide, and Medical Device Software Development: A Compliance Guide.
The FDA's cybersecurity requirements read like a compliance burden until you trace what they are actually built to prevent: a device compromise that reaches a patient, a data breach that triggers notification obligations, or a recall that damages both revenue and reputation. The February 3, 2026 final guidance is the second major revision in three years, which can look like regulatory churn, but it reflects how fast the threat landscape connected devices face is actually moving.
Framed as a cost, the guidance is a submission requirement. Framed as a business decision, it is closer to insurance against three specific failure modes:
- A Refuse to Accept determination that stalls market entry before review even begins.
- A postmarket vulnerability that surfaces after clearance with no coordinated disclosure process ready to respond.
- A recall triggered by a security gap that a threat model would have caught before the device shipped.
Manufacturers following a secure-by-design approach, building an SBOM early, running a documented risk assessment, and testing the update mechanism before submission, spend that effort once during development instead of paying for it twice through remediation after a deficiency letter or a field action. Standards like ANSI/AAMI SW96 (FDA Recognized Consensus Standard 13-131) and IEC 81001-5-1 exist precisely to give manufacturers a repeatable way to produce that evidence rather than reinventing the process for every submission.
The collaboration point matters here too. Software, hardware, and regulatory teams that coordinate from the start produce documentation that actually matches the shipped device, which is what a reviewer is checking for regardless of how the requirement is framed internally. Manufacturers that treat these rules as a shared engineering requirement, rather than a regulatory afterthought handed to compliance at the end, are the ones who see the least submission friction and the fewest costly surprises after clearance.
How Blue Goat Cyber Approaches This
We work with MedTech leadership to place cybersecurity spend where it changes the outcome, which is before architecture freeze, not after a deficiency letter arrives. Our team, including CISSP and OSCP-certified engineers with prior red-team backgrounds, builds the threat modeling, testing, and SBOM program as a scoped workstream against your actual submission timeline, aligned to the FDA's February 3, 2026 final premarket cybersecurity guidance and Section 524B.
For companies further along, we review what has already been filed and give a prioritized list of what is missing, what is weak, and what to fix first, so leadership can make an informed call on timeline and spend before the next deficiency letter rather than after. Our commitment: if the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our postmarket cybersecurity services.
Frequently Asked Questions
CTA
If your cybersecurity plan lives in a submission binder and nowhere else in the organization, that gap is a business risk before it is a technical one. Book a discovery session and we will help you size the investment against your actual timeline and exposure.
About the author
Christian Espinosa, MBA, CISSP · Founder & CEO, Blue Goat Cyber
U.S. Air Force Academy graduate and veteran with 30+ years in cybersecurity. Founded Alpine Security in 2014 (acquired 2020), then Blue Goat Cyber in 2022. Has supported 275+ FDA medical device submissions; no client has failed to clear due to cybersecurity. Author of three books including The Smartest Person in the Room. Ironman triathlete and mountaineer.